Welcome to our dedicated page for Apellis Pharmace SEC filings (Ticker: APLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apellis Pharmaceuticals, Inc. filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company with common stock registered under the Exchange Act. The company’s 8-K reports cover product revenue disclosures for SYFOVRE and EMPAVELI, cash and financial-condition updates, and material agreements related to collaborations, royalty arrangements, financing consents, and strategic transaction activity.
Apellis filings also record governance and compensation matters, including board appointments, director compensation, executive separation and retention plans, and related equity-award provisions. These documents disclose formal corporate actions, capital-structure references, material-event reporting, and the company’s public-company obligations as a Delaware issuer.
Apellis Pharmaceuticals appointed Mikael Dolsten, M.D., Ph.D., to its Board of Directors as a Class I director, effective March 1, 2026. He will serve until the 2027 annual stockholder meeting or until a successor is elected and qualified.
The Board determined that Dr. Dolsten is independent under Nasdaq rules. Upon joining, he received an option grant with a Black‑Scholes value of $300,000, vesting in three equal annual installments, and RSUs valued at $300,000 that vest after one year, all subject to continued service and full acceleration upon a change in control.
Apellis Pharmaceuticals is a commercial-stage biotech focused on complement inhibition, with two marketed C3‑targeting drugs: SYFOVRE for geographic atrophy (GA) and EMPAVELI for rare blood and kidney diseases.
In 2025, Apellis generated $586.9 million in U.S. net product revenue from SYFOVRE and $102.4 million from EMPAVELI, plus $13.2 million in royalties from partner Sobi. Net income was $22.4 million for 2025, compared with net losses of $197.9 million in 2024 and $528.6 million in 2023.
The company is expanding SYFOVRE globally, including approval in Australia, and advancing next‑generation GA therapy by combining SYFOVRE with siRNA APL‑3007. For EMPAVELI, Apellis is growing nephrology indications such as C3 glomerulopathy, primary IC‑MPGN, FSGS and delayed graft function. A July 2025 royalty buy‑down with Sobi brought a $275.0 million upfront payment and a $25.0 million EMA approval milestone, monetizing ex‑U.S. systemic pegcetacoplan royalties. As of June 30, 2025, non‑affiliate equity market value was $1.8 billion, and common shares outstanding were 127,829,909 as of February 17, 2026.
RTW Investments, LP and its managing partner Roderick Wong, M.D. reported beneficial ownership of Apellis Pharmaceuticals, Inc. common stock on a Schedule 13G. They report beneficial ownership of 7,666,764 shares of common stock, representing 6.1% of the outstanding class based on 126,525,218 shares outstanding as of October 23, 2025.
Both reporting persons have shared voting and shared dispositive power over these 7,666,764 shares, with no sole voting or dispositive power. The shares are held by certain funds advised by RTW Investments, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Apellis.
Apellis Pharmaceuticals Chief Business & Strat Officer Mark DeLong reported a small stock sale mainly for tax purposes. On February 11, 2026, he sold 368 shares of Apellis common stock at $22.1537 per share to cover tax withholding tied to Restricted Stock Units released on February 10, 2026. After this transaction, he directly owned 114,591 shares of Apellis common stock.
Apellis Pharmaceuticals insider plans small stock sale under Rule 144. A person associated with Apellis Pharmaceuticals plans to sell 368 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $8,152.56 and 126,525,218 shares outstanding.
The 368 shares were acquired on 02/10/2026 through restricted stock vesting from the issuer as compensation. In the past three months, Mark J. Delong has sold additional blocks of Apellis common stock, including 1,780 shares on 01/13/2026 and 3,371 shares on 01/22/2026, for disclosed gross proceeds.
BlackRock, Inc. has filed a Schedule 13G reporting beneficial ownership of 13,228,073 shares of Apellis Pharmaceuticals Inc. common stock, representing 10.5% of the class. BlackRock reports sole power to vote 13,026,072 shares and sole power to dispose of 13,228,073 shares.
The filing states the securities are held by certain BlackRock business units in the ordinary course of business and not for the purpose of changing or influencing control of Apellis. Various underlying clients have rights to dividends or sale proceeds, but no single client exceeds five percent of the outstanding common shares.
Apellis Pharmaceuticals Chief Executive Officer Cedric Francois reported an option exercise and related share acquisition. On 02/03/2026, a fully vested stock option for 8,840 shares of common stock was exercised at $3.76 per share, increasing his directly held common stock to 490,837 shares.
The filing also lists additional common stock positions held indirectly through several trusts, including The Cedric Francois Irrevocable Trust of 2023, The Cedric Francois Irrevocable Trust of 2023 - 2, The Francois Grossi Trust, and The Francois-DuBois Educational Trust, where he disclaims beneficial ownership except to the extent of any pecuniary interest.
Apellis Pharmaceuticals’ Chief People Officer Kelley Boucher received an equity grant of 30,146 shares of common stock in the form of restricted stock units on January 28, 2026. The award vests 25% each year over four years, subject to continued service.
Following this grant, Boucher beneficially owns 127,804 shares of Apellis common stock in direct ownership. This filing reflects routine equity-based compensation rather than an open-market purchase or sale.
Apellis Pharmaceuticals VP and Chief Accounting Officer James George Chopas reported an equity grant of 16,150 shares of common stock on January 28, 2026. The Form 4 shows the transaction coded as an acquisition at a price of $0 per share, tied to a restricted stock unit award.
According to the footnote, this award consists of restricted stock units that vest 25% each year over four years from the grant date, contingent on continued service. Following this grant, Chopas is shown as directly beneficially owning 65,955 shares of Apellis common stock.
Apellis Pharmaceuticals’ Chief Business & Strat Officer Mark DeLong received an award of 36,606 shares of common stock on January 28, 2026 as a restricted stock unit grant. These RSUs vest 25% each year over four years, contingent on continued service. Following this grant, DeLong directly beneficially owns 114,959 shares of Apellis common stock.